Baidu
map

APJCN:用机械通气的慢性阻塞性肺病患者测定的与预测的静息能量消耗之比较及临床应用分析

2013-12-04 佚名 亚太临床营养杂志

为了研究机械通气的慢性阻塞性肺病(COPD)患者的能量代谢特点,比较间接测热法测定与Harris-Benedict公式预测的静息能量消耗(REE)的差异。并以此为依据,分析低能量的营养支持是否能改善患者蛋白质营养状况。【原文下载】 纳入了33例(男20例,女13例)COPD患者,并测定其REE。比较测定的REE(REEm)和HB公式计算的REE(REEH-B)及其校正值之间的差异,同时还分析了R

为了研究机械通气的慢性阻塞性肺病(COPD)患者的能量代谢特点,比较间接测热法测定与Harris-Benedict公式预测的静息能量消耗(REE)的差异。并以此为依据,分析低能量的营养支持是否能改善患者蛋白质营养状况。【原文下载

纳入了33例(男20例,女13例)COPD患者,并测定其REE。比较测定的REE(REEm)和HB公式计算的REE(REEH-B)及其校正值之间的差异,同时还分析了REEm与APACHEⅡ评分之间的关系。33例患者被随机分成低能量组(REEm的50%-90%)和常规能量组(REEm的90%-130%),按照以上标准进行营养支持。比较营养支持前和支持后7天的白蛋白、前白蛋白、转铁蛋白、血红蛋白和淋巴细胞计数。REEH-B和用1.2校正的值均明显低于REEm(p < 0.01) ;REEm与APACHEⅡ评分之间存在正相关(p<0.05或p<0.01)。营养支持后,常规能量组的血红蛋白明显降低(p<0.05),两组患者的淋巴细胞计数,以及常规能量组的转铁蛋白和前白蛋白均明显升高(p<0.05或p<0.01)。

结果提示:1)机械通气的COPD患者的REE升高;2)间接测热法是确定REE的最好方法,在不能作间接测热法时,Harris-Benedict公式可用于计算患者的REE,但要参照APACHEⅡ评分予以校正;3)低能量的营养支持在改善机械通气COPD患者的蛋白质营养状况优于常规能量的营养支持。

原文出处

Rao ZY, Wu XT, Wang MY, Hu W.Comparison between measured and predicted resting energy expenditure in mechanically ventilated patients with COPD.Asia Pac J Clin Nutr. 2012【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671834, encodeId=e92116e183469, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Sep 01 08:33:00 CST 2014, time=2014-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835567, encodeId=4592183556e5f, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Dec 11 10:33:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696624, encodeId=8e051696624dc, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Aug 05 18:33:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662211, encodeId=a66816622118e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Mar 06 18:33:00 CST 2014, time=2014-03-06, status=1, ipAttribution=)]
    2014-09-01 amy0559
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671834, encodeId=e92116e183469, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Sep 01 08:33:00 CST 2014, time=2014-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835567, encodeId=4592183556e5f, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Dec 11 10:33:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696624, encodeId=8e051696624dc, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Aug 05 18:33:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662211, encodeId=a66816622118e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Mar 06 18:33:00 CST 2014, time=2014-03-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671834, encodeId=e92116e183469, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Sep 01 08:33:00 CST 2014, time=2014-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835567, encodeId=4592183556e5f, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Dec 11 10:33:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696624, encodeId=8e051696624dc, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Aug 05 18:33:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662211, encodeId=a66816622118e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Mar 06 18:33:00 CST 2014, time=2014-03-06, status=1, ipAttribution=)]
    2014-08-05 tomyang96
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671834, encodeId=e92116e183469, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Sep 01 08:33:00 CST 2014, time=2014-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835567, encodeId=4592183556e5f, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed Dec 11 10:33:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696624, encodeId=8e051696624dc, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Aug 05 18:33:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662211, encodeId=a66816622118e, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Mar 06 18:33:00 CST 2014, time=2014-03-06, status=1, ipAttribution=)]

相关资讯

β受体阻断剂在COPD的治疗或使用不足

    β受体阻断剂在慢性阻塞性肺病(COPD)的治疗中可能使用不足,而在急性心肌梗死的早期治疗中则存在使用过度的情况。     心血管疾病与COPD经由吸烟而形成了错综复杂的关系,然而对COPD患者使用β受体阻断剂却与传统观念相悖。多数医生都会避免这样做,哪怕患者合并心血管疾病,原因是担心β受体阻断剂诱发支气管痉挛和抵消β受体激动剂吸

Baidu
map
Baidu
map
Baidu
map